当前位置： SCI文献检索 > JOURNAL OF DIABETES AND ITS COMPLICATIONS期刊下所有文献 > Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Abstract：

BACKGROUND:Vulvovaginitis, balanitis, and related genital infections are common in patients with type 2 diabetes. Glucosuria, which is an outcome of treatment with sodium glucose cotransporter 2 (SGLT2) inhibitors, is among the possible causes. Dapagliflozin, an SGLT2 inhibitor with demonstrated glycemic benefits in patients with diabetes, has been studied across a broad spectrum of patients. Analysis of multi-trial safety data may better define the relationship between glucosuria and genital infection. METHODS:Safety data were pooled from 12 randomized, placebo-controlled Phase 2b/3 trials to analyze the association of glucosuria with genital infection in patients with suboptimally controlled diabetes (HbA1c >6.5%-12%). Patients were randomized to receive dapagliflozin (2.5mg, 5mg, or 10mg) or placebo once daily, either as monotherapy or add-on to metformin, insulin, sulfonylurea, or thiazolidinedione for 12-24weeks. The incidence of clinical diagnoses and of events suggestive of genital infection was evaluated. RESULTS:The pooled safety data included 4545 patients: 3152 who received once-daily dapagliflozin (2.5mg [n=814], 5mg [n=1145], or 10mg [n=1193]) as monotherapy or add-on treatment, and 1393 placebo-treated patients. For dapagliflozin 2.5mg, 5mg, 10mg, and placebo, diagnosed infections were reported in 4.1%, 5.7%, 4.8%, and 0.9%, respectively. Most infections were mild or moderate and responded to standard antimicrobial treatment. Discontinuation due to these events was rare. No clear dose-response relationship between dapagliflozin and genital infection was demonstrated. CONCLUSIONS:Treatment with dapagliflozin 2.5mg, 5mg, or 10mg once daily is accompanied by an increased risk of vulvovaginitis or balanitis, related to the induction of glucosuria. Events were generally mild to moderate, clinically manageable, and rarely led to discontinuation of treatment.

journal_name

J Diabetes Complications

journal_title

Journal of diabetes and its complications

authors

Johnsson KM,Ptaszynska A,Schmitz B,Sugg J,Parikh SJ,List JF

doi

10.1016/j.jdiacomp.2013.04.012

subject

Has Abstract

pub_date

2013-09-01 00:00:00

pages

479-84

issue

eissn

1056-8727

issn

1873-460X

pii

S1056-8727(13)00107-4

journal_volume

pub_type

杂志文章,meta分析

在线工具

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.